IFPMA Response to the WHO Fair Pricing Forum survey
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
Financing health systems: Leveraging the benefits of investing in prevention against NCDs
Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve population wellbeing. Evidence shows that every dollar invested in preventing and managing NCDs generates substantial returns through reduced healthcare costs, improved workforce participation, and healthier, more resilient societies. Yet despite this compelling investment case, progress remains...
Read moreThe innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
Policy considerations for the development, regulation and adoption of biosimilars
Biosimilars can play a role in expanding patient access to biological medicines and in supporting the sustainability of healthcare systems. To fully realize this potential, IFPMA recommends the adoption of a series of policy recommendations.
Read more